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Glaucoma is a progressive optic neuropathy characterized by visual field defects that
ultimately lead to irreversible blindness (Alward, 2000; Anderson et al., 2006). By the
year 2020, an estimated 80 million people will have glaucoma, 11 million of which
will be bilaterally blind. Primary open-angle glaucoma (POAG) is the most common
type of glaucoma. Elevated intraocular pressure (IOP) is currently the only risk factor
amenable to treatment. How IOP is regulated and can be modulated remains a topic
of active investigation. Available therapies, mostly geared toward lowering IOP, offer
incomplete protection, and POAG often goes undetected until irreparable damage has
been done, highlighting the need for novel therapeutic approaches, drug targets, and
biomarkers (Heijl et al., 2002; Quigley, 2011). In this review, the role of soluble (nitric
oxide (NO)-activated) and membrane-bound, natriuretic peptide (NP)-activated guanylate
cyclases that generate the secondary signaling molecule cyclic guanosine monophosphate
(cGMP) in the regulation of IOP and in the pathophysiology of POAG will be discussed.
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PRIMARY OPEN ANGLE GLAUCOMA
Primary open-angle glaucoma (POAG) is a leading cause of
blindness, affecting over 2.2 million patients in the US alone,
and is associated with an estimated health care cost upwards
of $1.5 billion/year. Vision loss, occurring due to loss of reti-
nal ganglion cells (RGCs) and degeneration of the optic nerve,
has far-reaching effects on the patient’s ability to function inde-
pendently, dramatically affecting quality of life from a physi-
cal, mental and social well-being perspective. Currently, there
is no definitive cure for POAG and although multiple risk
factors for POAG have been identified [including intra-ocular
pressure (IOP), race, age, and genetic factors], the molecu-
lar signaling involved in POAG pathogenesis remains largely
unknown.
Although multiple POAG risk factors have been identi-
fied, the etiology of POAG remains to be elucidated, likely
because the disease can be stratified into various subtypes
defined by discrete but yet unknown biochemical pathways.
Two major pathophysiologic mechanisms for POAG have
been proposed. In the “mechanical theory” optic neuropa-
thy is caused by increased IOP (see “Intraocular pressure:
a risk factor for POAG” below). Alternatively, a vascular
component has been hypothesized to contribute to POAG
pathophysiology (see “Glaucoma and vascular dysfunction”
below). However, the extent to which vascular dysfunction
contributes to glaucomatous optic neuropathy remains to
be elucidated and is controversial (Vajaranant and Pasquale,
2012).
INTRAOCULAR PRESSURE: A RISK FACTOR FOR POAG
POAG is often associated with elevated IOP. Measurement of IOP
typically requires an anesthetized ocular surface and a cooperative
patient, as corneal applanation is needed for accurate measure-
ment of this ophthalmic vital sign. While POAG is a strongly
age related disease (Sommer et al., 1991; Mukesh et al., 2002)
and elevated IOP is a major risk factor for this condition, IOP
does not necessarily increase with age. One longitudinal anal-
ysis found that among people aged 50–59, IOP increased after
9 years of follow-up but among subjects 60 and older, a slight
decrease in IOP was noted in the same time period (Wu et al.,
2006). Furthermore while African heritage is an undisputed risk
factor for POAG, people of African heritage do not necessarily
have higher IOP than Caucasian subjects drawn from the same
population (Sommer et al., 1991). While the heritability of IOP
is relative highly (56–64%) (Carbonaro et al., 2009) very few
common loci for this trait have been discovered thus far (Van
Koolwijk et al., 2012; Ozel et al., 2014). Other factors such as
body mass index (Klein et al., 1992; Wu and Leske, 1997; Oh
et al., 2005), blood pressure (Klein et al., 2005), and diabetes
(Wu et al., 2006) have only modest positive associations with
IOP. Data regarding how IOP might change while blood pres-
sure varies in an individual patient are lacking. When a patient
(regardless of glaucoma status) transitions between a seated to
supine position there is a predictable increase in IOP of ∼3mm
Hg (Lee et al., 2012, 2013). Only a few medical conditions impact
the level of IOP (Arevalo et al., 1996; Garcia Filho et al., 2011)
but steroid exposure is notorious for leading to elevated IOP via
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changes in trabecular meshwork permeability (Clark et al., 1995).
It is thought that IOP fluctuates more in POAG patients than
controls (Sacca et al., 1998) but the literature is conflicting regard-
ing the role of IOP fluctuation on open-angle glaucoma disease
progression (Nouri-Mahdavi et al., 2004; Bengtsson et al., 2007).
IOP is determined by the balance between the produc-
tion/secretion of aqueous humor (AqH) by the ciliary processes
and by the drainage of AqH via the iridocorneal angle. AqH
can exit the eye through various routes: the conventional, the
uveoscleral, and the uveolymphatic pathways. The conventional
pathway consists of the trabecular meshwork (TM), Schlemm’s
canal, collecting channels, and the episcleral venous system. It
is generally accepted that IOP reflects the pressure necessary
to overcome the intrinsic resistance to aqueous outflow that
occurs at the junction where the juxtacanalicular part of the TM
meets the inner wall of Schlemm’s canal (Ethier et al., 1986).
In uveoscleral outflow, AqH drains through the ciliary muscle
(CM) and exits through the supraciliary space and across the
anterior or posterior sclera, into choroidal vessels (Fautsch and
Johnson, 2006). Uveoscleral outflow, accounting for anywhere
between 3% and 80% of outflow depending on the species studied
(4–60% in humans) (Fautsch and Johnson, 2006), is particu-
larly impacted by age, an important observation considering the
age-dependency of POAG in both patients (Kass et al., 2002,
2010; Mukesh et al., 2002; De Voogd et al., 2005; Rudnicka et al.,
2006; Leske et al., 2008) and animal models (Buys et al., 2013).
Incidentally, also in animal models of secondary angle-closure
glaucoma, IOP and prevalence of optic neuropathy and retinal
lesions increased with age (John et al., 1998; Saleh et al., 2007).
More recently, the existence of a third outflow route was pos-
tulated: lymphatic channels in the stroma of the ciliary body
and interstitial spaces between CM muscle bundles may function
as a backup outflow system (Yucel et al., 2009). The relevance
of this uveolymphatic pathway and whether NO-cGMP signal-
ing (see “NO-cGMP signaling in the eye” below) modulates
contractility of ocular lymphatic vessels remains to be deter-
mined. Importantly, a central role for NO in lymphatic function
was recently identified (Liao et al., 2011). Whether the effect of
NO on lymphatic contractions is mediated by cGMP remains
unknown.
In contrast to what is observed in angle closure glaucoma,
POAG is not associated with apparent blockage of the anterior
chamber angle. In POAG, there is variable elevation of IOP asso-
ciated with impaired AqH outflow that occurs despite apparently
normal anterior segment anatomy and an open iridocorneal angle
(Weinreb and Khaw, 2004). IOP rises gradually over time, likely as
a consequence of decreased drainage of AqH. IOP-lowering treat-
ment significantly cuts the risk of developing glaucoma in ocular
hypertensives (Kass et al., 2002, 2010).
GLAUCOMA AND VASCULAR DYSFUNCTION
While IOP reduction continues to be a successful treatment to
reduce the progression of POAG (Leske et al., 2003; Kass et al.,
2010), the pathogenesis of POAG seemingly also depends on fac-
tors other than increased IOP. Compounds that do not lower
IOP dramatically may have properties that address the underly-
ing glaucomatous disease process and therefore could be suitable
therapeutic agents (Weinreb and Kaufman, 2009; Chen et al.,
2011). For example, brimonidine was superior to timolol in sta-
bilizing visual field deterioration, despite producing a similar
IOP-lowering effect (Krupin et al., 2011). Also, ocular hyperten-
sion does not necessarily lead to POAG and ocular normoten-
sion does not preclude the development of POAG (Leske et al.,
2001), suggesting that other pathologies, including neurologic
(similar to other chronic central nervous system diseases such
as Alzheimer’s diseases or Multiple Sclerosis Quigley, 2011) or
vascular dysfunction [e.g., as characterized by impaired retino-
vascular autoregulation (Feke and Pasquale, 2008) or peripheral
vascular endothelial dysfunction (Henry et al., 1999; Su et al.,
2008)], may contribute to the etiology of POAG. Vascular dys-
function contributes to the development of systemic hypertension
(Mendelsohn, 2005; Michael et al., 2008) and several studies have
provided evidence that blood pressure affects POAG risk (Kaiser
and Flammer, 1991; Tielsch et al., 1995; Hulsman et al., 2007;
Leske et al., 2008; Memarzadeh et al., 2010; Cherecheanu et al.,
2013). In addition, the idea that vascular dysfunction contributes
to the pathogenesis of POAG is based on the hypothesis that
decreased perfusion of the optic nerve leads to neurodegeneration
(Harris et al., 2005; Vajaranant and Pasquale, 2012).
Both impaired blood flow and impaired vascular autoregula-
tion have been described in glaucoma patients (Flammer et al.,
2002; Feke and Pasquale, 2008; Moore et al., 2008; Feke et al.,
2011). Large epidemiologic studies have found adverse associa-
tions between POAG and low ocular perfusion pressure (OPP)
(Hulsman et al., 2007; Leske, 2009) or low systemic blood pres-
sure (Bonomi et al., 2000). In addition, the Early Manifest
Glaucoma Trial observed that predictors of POAG disease pro-
gression included lower systolic blood and perfusion pressure
(Leske et al., 2007). Especially in normal tension glaucoma
patients, systemic vascular abnormalities have been described,
including impaired flow- or acetylcholine-mediated vasodilation
(Gasser and Flammer, 1991; Henry et al., 1999; Su et al., 2008).
Also POAG patients with early paracentral visual field loss are
more likely to have systemic vascular risk factors such as hypoten-
sion and migraines (Park et al., 2011, 2012). It is important to
note that blood flow regulation in the optic nerve head seems to
be strongly dependent on IOP and OPP (Schmidl et al., 2011).
The interaction between systemic blood pressure and IOP (defin-
ing OPP) (Tielsch et al., 1995; He et al., 2011) is particularly
relevant for this review, given the role of NO-cGMP signaling (see
“NO-cGMP signaling in the eye” below) in both the regulation of
IOP and systemic blood pressure.
NO-cGMP SIGNALING IN THE EYE
NO is an exceptionally well-characterized signaling molecule,
with important roles in a wide variety of physiological and patho-
physiological processes, including cardiovascular homeostasis,
neuronal function, and inflammation. NO is synthesized from
L-arginine by a family of three enzymes referred to as NO syn-
thases (NOSs) (Figure 1) (Moncada and Higgs, 1993). NOS2, or
inducible NOS, was first identified in macrophages but has since
been detected in a wide variety of cells exposed to endotoxin and
cytokines. Following bacterial infection, especially with gram-
negative organisms, high levels of NO are produced by NOS2.
NOS1 and NOS3 were initially described to be constitutively
expressed in neuronal cells and endothelial cells, respectively
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FIGURE 1 | Schematic of the Cyclic GMP (cGMP) signaling pathway.
cGMP is synthesized from GTP by soluble guanylate cyclases (sGCα1β1 or
sGCα2β1) in response to nitric oxide (NO) e.g., as generated by the conversion
of L-arginine (L-Arg) by NO synthase 3 (NOS3), or by the membrane guanylate
cyclase (natriuretic peptide) receptors (NPR) which are activated by peptide
hormones [e.g., atrial natriuretic peptide (ANP) and B-type natriuretic peptide
(BNP)]. cGMP binds to and activates cGMP-dependent protein kinase G (PKG)
and is hydrolyzed by phosphodiesterases (such as PDE5, the target for
sildenafil). The insets depict a schematic overview of the structure of NOS3,
NPR, PKG, PDE, and sGC.
(Moncada and Higgs, 1993). Under physiological conditions,
the low levels of NO produced by the two constitutive Ca2+-
dependent enzymes NOS1 and NOS3 have diverse functions
ranging from neurotransmission and vasodilatation to inhibi-
tion of platelet adhesion and aggregation. NO, is an important
modulator of smoothmuscle function and all three NOS isoforms
are expressed in the eye (Table 1). Multiple studies have reported
on the ability of NO to modulate resistance in the AqH out-
flow pathway and IOP (see “NO-cGMP-mediated regulation of
IOP: implications for POAG” below). Therefore, NO is an attrac-
tive candidate as a factor that could modify both mechanical and
vascular events in POAG pathogenesis.
NO has numerous targets, reacting with a variety of intra-
cellular and extracellular molecules typically via thiol groups
or transition metal centers (Chiamvimonvat et al., 1995; Torres
et al., 1995; Davis et al., 2001; Jaffrey et al., 2001; Stamler et al.,
2001). A major target of NO is the obligate heterodimer soluble
guanylate cyclase (sGC) (Mergia et al., 2003, 2006; Nimmegeers
et al., 2007; Vermeersch et al., 2007; Buys et al., 2008), a heme-
containing heterodimeric enzyme, consisting of one α and one
β subunit (Figure 1). cGMP interacts with a variety of effec-
tor proteins including cGMP-dependent protein kinases (PKGs),
cGMP-regulated phosphodiesterases (PDE’s), and ion channels.
cGMP is also synthesized by receptor guanylate cyclases that are
activated by NPs (NPRs, Figure 1). However, cGMP produced
by NPRs and sGC may have differential effects, possibly due to
differential spatiotemporal distributions of cGMP produced by
the two guanylate cyclase families (Su et al., 2005; Castro et al.,
2006; Piggott et al., 2006).
Two functional isoforms of sGC exist: sGCα1β1, the predom-
inant isoform in most tissues (Mergia et al., 2003), and sGCα2β1
(Hobbs, 1997; Russwurm et al., 1998; Bamberger et al., 2001).
sGCα and β subunits were shown to be expressed in several
anatomical sites relevant for glaucoma (Table 1 and Figure 2).
sGC activity was detected in rabbit (Haberecht et al., 1998), rat
(Kajimura et al., 2003), turtle (Blute et al., 1998), and mouse
retina (Blom et al., 2012; Buys et al., 2013). sGC is expressed both
in retinal ganglion cells and photoreceptors and in the vascular
smooth muscle layer of retinal arterioles. Finally, and most rele-
vant to the potential ability of NO-sGC tomodulate AqH outflow,
sGC is abundantly expressed in isolated human TM cells (Ellis
et al., 2009) and in both human and mouse CM (Buys et al.,
2013). Also NP-activated membrane bound guanylate cyclase are
expressed in various ocular tissues (see “NP receptors and their
effects on IOP” below and Table 1).
NO-cGMP-MEDIATED REGULATION OF IOP: IMPLICATIONS
FOR POAG
Multiple studies have yielded evidence suggesting that NO-cGMP
signaling regulates AqH outflow and IOP. For example, both
an NO donor and a cGMP-analog decreased IOP (Kotikoski
et al., 2002) and increased outflow facility in rabbits (Kotikoski
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Table 1 | Ocular localization of nitric oxide synthase (NOS), soluble guanylate cyclase (sGC), and NP receptors (NPR).
Gene Species Cell- or tissue type References
NOS1 Human Ciliary non-pigmented epithelium Nathanson and Mckee, 1995a
Human ONH astrocytes, lamina cribrosa Neufeld et al., 1997
Monkey Amacrine cells, rod and cone photoreceptors, RGC Haberecht et al., 1998
Canine RGC Franco-Bourland et al., 1998
Rabbit Amacrine cells, rod and cone photoreceptors, RGC Haberecht et al., 1998
Rat Ciliary process epithelium Yamamoto et al., 1993
Murine Retinal amacrine cells May and Mittag, 2004
Murine Retinal amacrine cells, RGC layer somata; IPL puncta Blom et al., 2012
Murine Müller cells Chen et al., 2013
NOS2 Human Macrophages in stroma and ciliary processes Nathanson and Mckee, 1995a
Human Astrocytes Liu and Neufeld, 2001
NOS3 Human Longitudinal CM fibers, TM, SC Nathanson and Mckee, 1995b
Human Retinal vasculature Neufeld et al., 1997
Human TM Fernandez-Durango et al., 2008
sGC Human RGC, IPL, ONL Buys et al., 2013
Human TM cells Ellis et al., 2009
Rabbit Amacrine cells, bipolar cells, cone photoreceptors, RGC Haberecht et al., 1998
Murine Somata in the INL, ONL, IPL, and OPL. Blom et al., 2012
Murine RGC, IPL, ONL Buys et al., 2013
Turtle Amacrine cells; bipolar cells, RGC layer, IPL Blute et al., 1998
NPR Rabbit Ciliary processes Mittag et al., 1987
Rabbit/bovine/human Corneal endothelium Walkenbach et al., 1993
Rabbit/rat Retina, choroid and ciliary process Fernandez-Durango et al., 1995
Human Retina Rollin et al., 2004
Bovine Choroid Schmidt et al., 2004
ONH, optic nerve head; RGC, retinal ganglion cell; IPL, inner plexiform layer; CM, ciliary muscle; TM, trabecular meshwork; SC, Schlemm’s canal; ONL, outer nuclear
layer; INL, inner nuclear layer; OPL, outer plexiform layer.
et al., 2003). The NO-induced increase in outflow facility was
impaired by treating perfused porcine eyes with the sGC inhibitor
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-1 (ODQ), suggesting
that the effects of NO on outflow are cGMP-dependent
(Ellis et al., 2009). The non-isoform specific NOS-inhibitor L-
NG-Nitroarginine methyl ester (L-NAME) decreased and an
NO-donor compound increased AqH flow rate in perfused
human donor eyes. This increase in flow was associated with an
increase in cGMP levels measured in the perfusate, again sug-
gesting a central role for sGC and cGMP in the ability of NO to
modulate outflow (Schneemann et al., 2002). Accordingly, NO-
donor compounds lower IOP (Nathanson, 1988, 1992; Schuman
et al., 1994; Behar-Cohen et al., 1996; Krauss et al., 2011) and
enhance tissue oxygenation of the optic nerve head in preclini-
cal animal models (Khoobehi et al., 2011). Overexpressing NOS3
in mice lowers IOP by increasing pressure-dependent drainage
(Stamer et al., 2011), confirming previous reports suggesting that
the ability of NO to lower IOP is mediated by a decrease in the
AqH resistance rather than a change in the rate of AqH secretion
(Nathanson and Mckee, 1995b). Other possible mechanisms by
which NO and cGMP can modulate outflow include regulation
of Schlemm’s canal cell volume (Dismuke et al., 2008; Ellis et al.,
2010) and TM cell volume (Dismuke et al., 2009).
Impaired NO-cGMP signaling has been implicated in POAG.
For example, NO metabolites and cGMP levels were lower in
both plasma and AqH samples from POAG patients than in
those from individuals without POAG (Galassi et al., 2000, 2004;
Doganay et al., 2002). Also, NADPH-diaphorase (NADPH-d)
reactivity, a marker for NO production, was decreased in TM,
SC, and anterior longitudinal CM fibers isolated from POAG eyes
(Nathanson and Mckee, 1995a) and serum levels of L-arginine
analogs (endogenous NOS inhibitors) were found to be elevated
in patients with advanced glaucoma (Javadiyan et al., 2012).
In addition, NOS3 gene variants were associated with POAG
in women (see “Genetics of POAG” below Kang et al., 2010;
Magalhaes Da Silva et al., 2012). Together, these studies suggest
that impaired NO-cGMP signaling can contribute to the etiol-
ogy of POAG, identifying the NO-cGMP signaling pathway as a
potential therapeutic target for POAG. However, the molecular
mechanismsmediating cGMP’s effects in the eye, and exactly how
NO-cGMP signaling regulates IOP or impacts optic neuropathy
remain unclear.
It is important to recognize that the role of NO-cGMP sig-
naling in the eye is likely complex with physiological and patho-
physiological effects. For example, contrary to the observations
described above that NO lowers IOP, topical application of the
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FIGURE 2 | Schematic of the eye with anatomical sites relevant for
the development of POAG in which sGC is expressed indicated.
Sections through retinal ganglion cells, ciliary muscle and a retinal
arteriole from a human eye were stained for sGCα1 (green), α-smooth
muscle actin (red), and/or DAPI nucleic acid stain (blue). Both sGCα1 and
sGCβ1 (not shown) co-localized with a-smooth muscle actin in ciliary
muscle and the smooth muscle cell layer of a retinal arteriole (yellow in
merged images). In addition, sGCα1 and sGCβ1 (not shown) expression
was detected histologically in the outer nuclear layer, inner nuclear layer,
and ganglion cell layer of the retina.
NOS-inhibitor L-NAME reduced IOP in a rabbit model of ocu-
lar hypertension (Giuffrida et al., 2003). This reduction of IOP,
observed only in hypertensive eyes and not normotensive con-
trols, was suggested to be associated with a decreased formation
of AqH production (Giuffrida et al., 2003). Opposing effects of
cGMP itself on AqH dynamics have been reported: AqH flow
rate decreased after intravitreal administration of the cell perme-
able cGMP analog 8-Br-cGMP but increased after intra-cameral
administration of 8-Br-cGMP, underscoring that the route of
administration of any drug aimed at lowering IOP or preventing
POAG progression may significantly determines its therapeutic
efficacy (Kee et al., 1994).
NO MODULATES RGC VIABILITY
NO can also exert a direct neurotoxic effect on RGC’s (Morgan
et al., 1999; Takahata et al., 2003). For example, in acute angle-
closure glaucoma patients, higher levels of NO in AqH were
postulated to contribute to RGC and optic nerve damage (Chang
et al., 2000; Chiou et al., 2001). Similarly, in a rat model of chronic
glaucoma, elevated retinal NOS1 expression was suggested to con-
tribute to cytotoxicity and selective RGC loss (Park et al., 2007).
Furthermore, NO generated by NOS2 can contribute to RGC
death seen in response to increased IOP: treatment of rats with
chronically elevated IOP with an inhibitor of NOS2 prevented
RGC loss (Neufeld et al., 1999, 2002). More clinically relevant,
expression of NOS2 was increased in the TM of POAG patients
and activity of NOS2 in the TM of patients with POAG was
reported to be proportional to the observed visual field defects
(Fernandez-Durango et al., 2008). Together, these data could be
interpreted to suggest that inhibiting NOS activity may be use-
ful for the treatment of glaucoma by protecting RGCs from stress
(e.g., as associated with elevated IOP). However, as described
in the studies referred to above, there is ample evidence that
impaired NO-cGMP signaling contributes to the pathogenesis of
POAG. Together with the fact that NO has multiple downstream
targets, of which sGC is arguably a predominant one, these obser-
vations support focusing on sGC and cGMP as therapeutic targets
in POAG (see “The NO-cGMP pathway as a therapeutic target for
POAG” below).
MODULATION OF TM AND CM CONTRACTILITY BY
NO-cGMP AND ITS RELEVANCE IN IOP REGULATION
It is generally accepted that the TM and CM are active structures
rather than passive filters. The CM is a smooth-muscle like struc-
ture and the TM contains contractile smooth-muscle-specific
alpha-actin filaments. Both are involved in fine-tuning the regu-
lation of AqH outflow (Erickson-Lamy et al., 1991; Wiederholt,
1998; Wiederholt et al., 2000). Several studies (reviewed in
Wiederholt et al., 2000) have suggested the existence of a func-
tional antagonism between the TM and the CM, and TM resis-
tance may be regulated by contractile state of CM (Nathanson
and Mckee, 1995b): contraction of the CM would decrease TM
resistance, increase AqH outflow and decrease IOP.
Alterations in smooth muscle contractility have previ-
ously been implicated in glaucoma. For example, RhoA-Rho
kinase-mediated signaling, which regulates the phosphorylation
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status of myosin light chain, thereby directly influencing TM con-
traction, was reported to influence AqH drainage (Russ et al.,
2010). Inhibiting Rho kinase, an enzyme that plays a critical
role in regulating the contractile tone of smooth muscle tissues,
increased AqH outflow in various animal models (Honjo et al.,
2001; Rao and Epstein, 2007; Lu et al., 2008). The ability of Rho-
kinase inhibitors to lower IOP is currently being tested in clinical
trials (Chen et al., 2011; Tanihara et al., 2013).
The presence of NOS3 and sGC in the CM and TM (Table 1)
suggest that the NO-sGC pathway may modulate outflow resis-
tance by regulating CM and TM contractility. In fact, both
NO-donor compounds and a cGMP analog were previously
demonstrated to regulate the contractile state of bovine CM
and TM in organ bath experiments (Wiederholt et al., 1994;
Masuda et al., 1997; Kamikawatoko et al., 1998). The abil-
ity of NO-cGMP to regulate smooth muscle cell relaxation is
well known. For example, vascular reactivity was attenuated in
NOS3 mutant mice (Atochin et al., 2007) and in sGCα−/−1 mice
(Mergia et al., 2006; Nimmegeers et al., 2007). NO-cGMP sig-
naling (facilitating smooth muscle relaxation Surks et al., 1999)
and RhoA-Rho kinase signaling (causing smooth muscle con-
traction Bennett et al., 1988) have opposing effects on smooth
muscle function and NO-cGMP signaling controls activity of
the RhoA-Rho kinase pathway (Sauzeau et al., 2003). Together,
these findings raise the possibility that impaired NO-cGMP sig-
naling, previously suggested to participate in the regulation of
AqH outflow and IOP (see “NO-cGMP-mediated regulation of
IOP: implications for POAG” above) has a similar impact on AqH
drainage as does increased RhoA-signaling: both could result in
augmented contractility of the smooth muscle-like CM, thereby
potentially decreasing AqH drainage and increasing IOP (Honjo
et al., 2001).
There is, however, an apparent paradox in the dynamic reg-
ulation of IOP by the CM and the role of NO-cGMP therein:
impaired NO-cGMP signaling would be expected to result in a
decreased ability of the SMC-like CM to relax, just as it does in
other SMC-like structures (Mergia et al., 2006; Friebe et al., 2007;
Nimmegeers et al., 2007; Vanneste et al., 2007; Decaluwe et al.,
2010), and hence decrease TM resistance. Importantly, there are
two types of CM in humans: circular, involved in accommoda-
tion, and longitudinal (Flugel et al., 1990; Sharif et al., 2004).
The effect of CM contraction and relaxation on IOP is not uni-
form: the circular and longitudinal components of the CM appear
to have opposite roles in controlling IOP. Contraction of the
circular muscle via muscarinic stimulation (e.g., in response to
pilocarpine) causes tightening of the trabecular ring leading to
an opening of the trabecular juxtacanalicular tissue, decreased
resistance, and increased outflow facility, ultimately lowering IOP
(Kaufman, 2008). On the other hand, there is evidence that
contraction of the longitudinal muscle can impair outflow and
increase IOP. The latter was demonstrated in patients that suf-
fered significant blunt trauma where the circular CM is disabled
without affecting the longitudinal muscle. When these patients
were treated with pilocarpine, the contraction of the longitudi-
nal muscle paradoxically increased IOP (Bleiman and Schwartz,
1979). Therefore, relaxation of the posterior longitudinal mus-
cle in the CM (e.g., with Rho-kinase inhibitors Honjo et al.,
2001) likely has an outflow enhancing effect, lowering IOP. On the
other hand, decreased relaxation of longitudinal CMfibers associ-
ated with impaired NO-cGMP signaling (e.g., in sGCα−/−1 mice,
see “sGC-deficient mice: a model of elevated IOP and POAG”
below), would result in increased IOP. In addition, repeated
contraction and NO-mediated relaxation of any CM component
may decreases outflow resistance and lower IOP, likely due to
a direct mechanical effect on the TM. Lack of NO-sGC-cGMP
signaling in the CM may prevent flushing of the TM, possibly
resulting in altered (increased) outflow resistance.
THE NO-cGMP PATHWAY AS A THERAPEUTIC TARGET FOR
POAG
The NO-cGMP pathway can be perturbed by a variety of mech-
anisms. Decreases in NOS3 expression or uncoupling of NOS3
result in lower NO levels (Takimoto et al., 2005). Alternatively,
NO bioavailability can be reduced by interaction of NO with
reactive oxygen species (ROS) (Munzel et al., 2010). sGC itself
can be converted to an NO-insensitive state as a consequence of
increased oxidative stress: it is conceivable that the mechanism
by which increased oxidative stress results in POAG (Majsterek
et al., 2011a) may involve direct oxidation and inactivation of
sGC (Stasch et al., 2006). Also, sGC expression can be repressed
under pro-inflammatory conditions (Marro et al., 2008). The
latter is relevant based on the hypothesis that inflammation con-
tributes to the development of glaucoma (Vohra et al., 2013).
Lastly, NO-cGMP signaling can be modulated by genetic varia-
tion (see “Genetics of POAG” below) (Kang et al., 2010, 2011;
Ehret et al., 2011; Buys et al., 2013). Whether any of the mech-
anisms that alter activity of the NO-cGMP pathway contribute
to the etiology of POAG remains a matter of active investigation.
Nonetheless, the studies described here and in the “Modulation
of TM and CM contractility by NO-cGMP and its relevance in
IOP regulation” section certainly imply the potential usefulness
of focusing on NO-cGMP signaling as a therapeutic approach to
the treatment of POAG.
Various therapeutic agents have been and are being devel-
oped to enhance NO-sGC-cGMP signaling. NO-independent
sGC stimulators are already being clinically tested and have been
approved for treating cardiovascular disease (Ghofrani et al.,
2013). These compounds could conceivably be developed to
treat POAG. NO-independent and heme-independent sGC acti-
vators preferentially activate sGC when the heme is oxidized or
missing (Stasch et al., 2006). The selectivity of sGC activators
for oxidized/heme-free sGC could be exploited therapeutically
to preferentially target diseased tissue (Boerrigter et al., 2007),
especially since oxidative stress may have a pathogenic role in
POAG (Majsterek et al., 2011a). Another advantage of specifically
activating sGC is that it bypasses any toxicity associated with acti-
vating NOS (see “NO-cGMP-mediated regulation of IOP: impli-
cations for POAG” above). In addition, targeting sGC rather than
NOS circumvents concerns related with reduced NO bioavail-
ability (e.g., in a setting of increased oxidative stress) and allows
for a more specific approach since the biological actions of NO
are not only mediated by cGMP but also by cGMP-independent
mechanisms.
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Other potential therapeutic approaches specifically aimed at
cGMP signaling that may be developed for treatment of POAG
include targeting other enzymes that control GMP levels and
which are abundantly present in the eye, including cGMP-
catabolizing PDE’s (Francis et al., 2011) and NP activated mem-
brane bound guanylate cyclades (see “NP receptors and their
effects on IOP” below, Mckie et al., 2010). Pilot studies testing
the ability of the PDE5 inhibitor sildenafil to lower IOP were
not successful. A single oral dose of 50–100mg sildenafil failed
to impact IOP in POAG patients (Grunwald et al., 2001) and
healthy volunteers (Vobig et al., 1999; Sponsel et al., 2000), but did
increase blood flow in both healthy subjects (Sponsel et al., 2000;
Foresta et al., 2008) and patients with systemic vascular dysfunc-
tion (Koksal et al., 2005). Also chronic treatment with sildenafil
(twice per week for 3 months) failed to impact IOP (Dundar
et al., 2006). It is noteworthy that the cohorts in which the effect
of sildenafil on IOP was studied were of limited size (5–15 sub-
jects). It is conceivable that these studies were underpowered to
detect small decreases in IOP associated with sildenafil treatment.
This is a relevant concern since modest changes in IOP have been
reported to impact POAG risk in humans. For example, a 2-
mmHg difference in IOP distinguished between progression and
non-progression in POAG patients (Leske et al., 2007; Konstas
et al., 2012). Also, most of the cohorts studied consisted of men
only. In light of a possible gender-specificity of POAG (Vajaranant
et al., 2010; Pasquale and Kang, 2011; Tsai et al., 2012) and the role
of NO-cGMP signaling therein (Kang et al., 2010), it would be
of interest to see whether preventing cGMP catabolism by PDE5
would impact IOP in women. Finally, the half-life of sildenafil is
rather limited (∼4 h) (Smith et al., 2013). It may be worthwhile
testing the effect on IOP of other PDE5 inhibitors with longer
half-lives (e.g., tadalafil with a half-life of ∼17 h Smith et al.,
2013) and/or performing a carefully controlled dose response
experiment. Finally, various methods to deliver the drug should
be tested. Whether pharmacological modulation of the activity
of enzymes that ultimately modulate cGMP levels may prevent
POAG progression remains to be determined.
sGC-DEFICIENT MICE: A MODEL OF ELEVATED IOP AND
POAG
Mice lacking the α1 subunit of the NO receptor soluble guany-
late cyclase (sGCα−/−1 mice) were recently reported to represent
a novel and translatable animal model of POAG, characterized
by thinning of the retinal nerve fiber layer (RNFL) and loss of
optic nerve axons (Buys et al., 2013). The optic neuropathy asso-
ciated with sGCα1—deficiency was accompanied by modestly
increased IOP, on average 2mmHg higher in 39 ± 14 weeks
old female sGCα−/−1 mice than in age-matched female wild-type
(WT)mice. No IOP difference was detected between age-matched
15 ± 6 weeks old female sGCα−/−1 and age-matched WT mice:
age was a predictor of elevated IOP in female sGCα−/−1 but
not in WT mice. The increase in IOP was accompanied by a
decrease in AqH turnover in the context of an open iridocorneal
angle: sGCα−/−1 mice presented with a normal ciliary body, a
well-defined TM, and a patent Schlemm’s canal. In addition,
spectral domain optical coherence tomography analysis of the
iridocorneal angle did not reveal any evidence for angle-closure in
sGCα−/−1 mice. Similarly, biomicroscopy did not reveal any evi-
dence of exfoliation syndrome, pigment dispersion syndrome, or
other conditions that could produce elevated IOP.
Highlighting the multi-faceted role of NO-cGMP signaling
in ocular (patho)physiology, retinal vascular dysfunction was
observed in sGCα−/−1 mice. Other studies had postulated that
vascular dysfunction contributes to the etiology of POAG (Henry
et al., 1999; Feke and Pasquale, 2008; Su et al., 2008) and systemic
vascular dysfunction had been previously reported in sGCα−/−1
mice (Nimmegeers et al., 2007; Atochin et al., 2010; Buys et al.,
2012). Whether retinal vascular dysfunction underlies the reti-
nal degeneration and optic neuropathy in sGCα−/−1 mice remains
to be determined. Vascular dysfunction may also contribute to
the observed increases in IOP in sGCα−/−1 mice, possibly by
impairing uveolymphatic outflow (see “Intraocular pressure: a
risk factor for POAG” above). Finally, it cannot be excluded that
loss of RGCs in sGCα−/−1 mice is caused by a direct effect of sGC-
deficiency on RGCs, possibly modulating the susceptibility of
RGCs to stress imposed by increased IOP or vascular dysfunction.
Taken together, targeting sGC may represent a multi-pronged
approach, aimed at lowering IOP, ameliorating vascular func-
tion, and protecting RGCs from stress-induced dysfunction and
death. To test this hypothesis, additional studies, including in ani-
mal models of POAG, such as the sGCα−/−1 mouse model, are
required.
GENETICS OF POAG
First-degree relatives of glaucoma patients have a 22% risk of
developing glaucoma versus a 2% lifetime risk of relatives of
controls (Wolfs et al., 1998). In recent years, familial aggrega-
tion, genome wide and candidate gene association studies have
uncovered an important genetic component to POAG (Table 2).
Several dozen genetic loci have been linked to POAG (Fan et al.,
2006). The role of many of the identified genes in the etiol-
ogy of POAG, some of which were identified in single studies
that need to be replicated, remains controversial. Among the
genes identified to date, three are involved in the nitric oxide
(NO)-cGMP system, highlighting a central role of this signaling
pathway in the development of POAG. First, variants were identi-
fied in or near the genes encoding caveolin 1 and 2 (CAV1/CAV2)
(Thorleifsson et al., 2010; Wiggs et al., 2011). Caveolins mod-
ulate the ability of NOS3 to generate NO (Mineo and Shaul,
2012). At least one variant in the CAV1/CAV2 locus was subse-
quently found to be associated with increased IOP (Van Koolwijk
et al., 2012; Ozel et al., 2014). Second, A candidate gene asso-
ciation study in 527 incident cases and 1543 controls revealed
interactions between NOS3 gene variants, potentially affecting
expression and/or activity of NOS3, and high tension POAG in
females (Kang et al., 2010). In addition, a functional NOS3 poly-
morphism (T-786C) was associated with POAG and appears to
interact with gender and age in modulating the risk of POAG
(Magalhaes Da Silva et al., 2012). The same variant also affects the
interaction of systemic hypertension and cigarette smoking with
POAG risk, highlighting the complex gene-environment interac-
tions that impact the etiology of POAG (Kang et al., 2011). And
Frontiers in Molecular Neuroscience www.frontiersin.org May 2014 | Volume 7 | Article 38 | 7
Buys et al. Guanylate cyclases and POAG
Table 2 | POAG-associated genes.
Gene Association References Remarks
AGTR2 NTG Hashizume et al., 2005 CGAS, interaction with gender
APOE POAG Copin et al., 2002 CGAS
ASB10 POAG Pasutto et al., 2012 Family-based linkage study
ATOH7 POAG Ramdas et al., 2011; Chen et al., 2012 CGAS, interactive effect with RFTN1
C7 POAG Scheetz et al., 2013 GWAS
CAV1/CAV2 POAG Thorleifsson et al., 2010 GWAS, also associated with IOP (Ozel et al., 2014)
POAG Wiggs et al., 2011 CGAS, interaction with gender, also associated with IOP (Ozel et al.,
2014)
CDKN1A POAG Tsai et al., 2004 CGAS
CDKN2B-AS1 POAG Ramdas et al., 2011 CGAS
POAG Burdon et al., 2011 GWAS, also associated with IOP (Ozel et al., 2014)
POAG Nakano et al., 2012 GWAS, also associated with IOP (Ozel et al., 2014)
POAG, NTG, XFG Wiggs et al., 2012 GWAS, also associated with IOP (Ozel et al., 2014)
CYP1B1 JOAG Vincent et al., 2002 CGAS
EDNRA NTG Ishikawa et al., 2005 CGAS
ELOVL5 NTG Meguro et al., 2010 GWAS
GAS7 POAG Van Koolwijk et al., 2012 CGAS, SNP identified in IOP GWAS
GLC1B POAG Stoilova et al., 1996 Family-based linkage study
GSTM1 POAG Juronen et al., 2000 CGAS
HK2 POAG and NTG Shi et al., 2013 CGAS
IGF2 POAG Tsai et al., 2003 CGAS
IL1B POAG Lin et al., 2003b CGAS
LOXL1 XFG Thorleifsson et al., 2007 GWAS, not associated with POAG
MMP1 POAG Majsterek et al., 2011b CGAS
MTHFR POAG Junemann et al., 2005 CGAS
MYOC JOAG Sheffield et al., 1993; Stone et al., 1997 Family-based linkage study
NCK2 NTG Shi et al., 2013 CGAS
NOS3 POAG Tunny et al., 1998 CGAS
HTG Kang et al., 2010 CGAS, interaction with gender and hormone use
POAG Kang et al., 2011 CGAS, interaction with hypertension and smoking
NPPA POAG Tunny et al., 1996 CGAS
OCLM POAG Fujiwara et al., 2003 CGAS
OPA1 NTG Aung et al., 2002 CGAS
OPTN NTG Sarfarazi et al., 1998; Rezaie et al., 2002 Family-based linkage study
Six1/Six6 POAG Ramdas et al., 2011 CGAS
POAG Wiggs et al., 2012 GWAS, also associated with IOP (Ozel et al., 2014)
SRBD1 NTG Meguro et al., 2010 GWAS
TAP1 POAG Lin et al., 2004 CGAS
TMCO1 POAG Burdon et al., 2011 GWAS, also associated with IOP (Van Koolwijk et al., 2012; Ozel et al.,
2014)
TNF POAG Lin et al., 2003a CGAS
TP53 POAG Lin et al., 2002 CGAS
WDR36 POAG Monemi et al., 2005 CGAS
AGTR2, Angiotensin II receptor type 2; APOE, Apolipoprotein E; ASB10, ankyrin repeat and SOCS box-containing 1; ATOH7, atonal homolog 7; C7, complement
component 7; CAV1, caveolin 1; CAV2, caveolin 2; CDKN1A, cyclin-dependent kinase inhibitor 1A; CDKN2B-AS1, CDKN2B antisense RNA 1; CGAS, candidate gene
association study; CYP1B1, cytochrome P450 subfamily I polypeptide 1; EDNRA, endothelin receptor type A; ELOVL1, elongation of very-long-chain-fatty acids
1; GAS7, growth arrest-specific protein 7; GLC1B, glaucoma 1, open angle, B; GSTM1, glutathione S-transferase mu-1; GWAS, genome-wide association study;
HK2, hexokinase 2; HTG, high-tension glaucoma; IGF2, insulin-like growth factor II; IL1B, interleukin 1-beta; IOP, intra-ocular pressure; JOAG, juvenile open angle
glaucoma; LOXL1, lysyl oxidase-like 1; MMP1, matrix metalloproteinase 1; MTHFR, 5,10-methylenetetrahydrofolate reductase; MYOC, myocilin; NCK2, NCK adaptor
protein 2; NOS3, nitric oxide synthase 3; NPPA, natriuretic peptide precursor; NTG, normal-tension glaucoma; OCLM, oculomedin; OPA1, optic atrophy 1; OPTN,
optineurin; POAG, primary open angle glaucoma; RFTN1, raftlin lipid raft linker 1; Six1/Six6, six homeobox1/6; SRBD1, S1 RNA-Binding Domain-Containing Protein 1;
TAP1, transporter ATP-binding cassette major histocompatibility complex 1; TMCO1, transmembrane and coiled-coil domains 1; TNF, tumor necrosis factor; TP53,
tumor protein p53; WDR36, WD repeat domain 36; XFG, exfoliation glaucoma.
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thirdly, in a recent candidate gene association study in POAG
patients from the GLAUGEN cohort (Wiggs et al., 2011), a vari-
ant (rs11722059) was identified in theGUCY1A3/GUCY1B3 locus
(containing the genes encoding the α1 and β1 subunits of sGC,
arranged in tandem) (Wiggs et al., 2011). Intriguingly, the associ-
ation was only present in POAG characterized by early paracentral
visual field loss (Buys et al., 2013). Early paracentral visual field
loss is a subtype of POAG previously postulated to be associated
with ocular vascular dysregulation (Park et al., 2011). This was
a particularly interesting finding in light of the identification of
sGCα−/−1 mice with systemic and retinal vascular dysfunction,
as a model of POAG with moderately elevated IOP: as described
above, POAG patients with early paracentral visual field loss tend
to have more frequent systemic vascular risk factors (Park et al.,
2011, 2012), and low OPP is a risk factor for POAG (Leske, 2009;
Cherecheanu et al., 2013). In addition, rs11722059 is in linkage
disequilibrium with a GUCY1A3/GUCY1B3 variant associated
with blood pressure in a large genome wide association study
(GWAS) (Ehret et al., 2011). However, the extent to which vas-
cular dysfunction contributes to glaucomatous optic neuropathy
remains to be elucidated (Flammer et al., 2002; Vajaranant and
Pasquale, 2012).
For neither the NOS3 or GUCY1A3/GUCY1B3 variants, an
association with IOP was detected. Whether this truly means
that there is no association with the identified variants remains
unsure: it is conceivable that the GWAS and candidate gene asso-
ciation studies discussed were underpowered to detect small effect
on IOP. For example, the GWAS in which the sGC blood pres-
sure variant was identified included 200,000 subjects (Ehret et al.,
2011). In contrast, the studies aimed at identifying associations
with POAG and IOP (like systemic blood pressure a continu-
ous variable) were much smaller in scope (hundreds to several
thousand subjects).
NP RECEPTORS AND THEIR EFFECTS ON IOP
There are three NPs in mammals: atrial NP, B-type NP and C-
type NP (Potter et al., 2009). A separate gene encodes each NP,
and mouse “knock out” experiments have shown that each NP
has unique functions, although all members stimulate vasore-
laxation. ANP and BNP are cardiac endocrine hormones that
decrease blood pressure and volume. CNP is a paracrine-signaling
molecule that stimulates long bone growth, causes bifurcation of
neurons in the spinal cord and inhibits meiosis in the oocyte.
There are also three known NP peptide receptors (Potter,
2011a,b,c). The natriuretic clearance receptor (NPR-C) controls
the local concentration of all three natriuretic peptides through
an undefined receptor-mediated internalization and degradation
process, but it has also been reported to signal through a G-
protein-dependent pathway. The primary signaling receptor for
ANP and BNP is guanylate cyclase-A (GC-A), which is also
known as natriuretic peptide receptor-A or NPR1. It consists
of an extracellular ligand-binding domain, a single membrane-
spanning region and intracellular guanylate cyclase domain. GC-
B, also known at NPR-B or NPR2, is the primary signaling
receptor for CNP and it is topologically and structurally similar to
GC-A. The vast majority of NPs functions are mediated through
elevation of intracellular cGMP concentrations synthesized by the
guanylate cyclase domains of GC-A or GC-B.
Early studies reported that binding sites for 125I-ANP were
found in rat and rabbit ciliary processes (Bianchi et al., 1986).
Shortly thereafter, topical, intracameral and intravitreal appli-
cation of ANP was shown to decrease IOP in rabbits (Sugrue
and Viader, 1986). The pressure reductions were longer lasting
with the intravitreal treatments but even the topical applica-
tion reduced IOP. Additional studies found that ANP stimulated
guanylate cyclase activity in ciliary processes of the rabbit eye and
that intravitreous injection of ANP decreased IOP in the rabbit
eye for up to 24 h (Mittag et al., 1987). The reduction of IOP by
intravitreal ANP was later correlated to a decrease in AqH flow in
the rabbit eye (Korenfeld and Becker, 1989).
Relatively low concentrations of CNP (∼2 nmol/L) were also
shown to increase cGMP concentrations in the AqH of the rabbit
eye and reduce IOP in rabbit eyes by a process associated with an
increase in total outflow facility (Takashima et al., 1998). In the
same study, CNP-like immunoreactivity was detected in rabbit
and porcine AqH at about two-fold higher concentrations than
that found in plasma. In a more recent study, CNP was shown
to be a more potent reducer of IOP than ANP in rabbit eyes,
and a ring-deleted analog of ANP that blocked binding to NPR-
C and increased the concentration of all endogenous natriuretic
peptides, maintained IOP reductions longer that other natriuretic
peptides (Fernandez-Durango et al., 1999). Thus, whether the
reductions in IOP observed by early investigators were due to
cross-activation of GC-B or whether activation of GC-B and GC-
A leads to decreased IOP is not known. Regardless, CNP is the
most potent natriuretic peptide for reducing IOP in mammals,
which suggests that the degradation resistant CNP analog devel-
oped for the treatment of achondroplasiamay be an ideal peptide-
based molecule to reduce IOP in the clinic (Lorget et al., 2012).
CONCLUSION
In conclusion, POAG remains a major cause of blindness in
the USA and worldwide. The identification of new therapeutic
targets for the treatment of POAG has been hampered by lack
of understanding of the etiology of POAG and the limited
number of animal models available that likely represent only a
small subset of human POAG cases. There continues to be an
urgent need for biomarkers that allow to detect/diagnose/track
POAG progression and treatment efficacy. Also, the lack of a
definitive cure underscores the need to develop novel therapeutic
approaches for POAG.
Evidence obtained from animal models indicates that cGMP
signaling plays an important role in POAG pathogenesis. These
findings are supported by genetic studies of IOP and POAG risk
in human subjects, highlighting the relevance of cGMP signal-
ing in the development of POAG. Strategies aimed at modulating
cGMP levels may constitute a pharmacological approach for a dis-
ease for which no definitive cure is currently available. However,
additional studies are required to unequivocally determine the
role of impaired cGMP signaling in POAG and to advance bench-
to-bedside translation of available cGMP-enhancing reagents.
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